JP2001504461A - 治療有効成分として脂肪酸類もしくは脂肪族アルコール類またはそれらのモノグリセライド誘導体を含有する粘膜感染症治療用局所製剤 - Google Patents

治療有効成分として脂肪酸類もしくは脂肪族アルコール類またはそれらのモノグリセライド誘導体を含有する粘膜感染症治療用局所製剤

Info

Publication number
JP2001504461A
JP2001504461A JP52206398A JP52206398A JP2001504461A JP 2001504461 A JP2001504461 A JP 2001504461A JP 52206398 A JP52206398 A JP 52206398A JP 52206398 A JP52206398 A JP 52206398A JP 2001504461 A JP2001504461 A JP 2001504461A
Authority
JP
Japan
Prior art keywords
formulation
lipid
titer
concentration
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP52206398A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001504461A5 (enExample
Inventor
ハルドー ソーマー
ソルディス クリストマンドスドティア
Original Assignee
リポメディカ イーエイチエフ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リポメディカ イーエイチエフ． filed Critical リポメディカ イーエイチエフ．
Publication of JP2001504461A publication Critical patent/JP2001504461A/ja
Publication of JP2001504461A5 publication Critical patent/JP2001504461A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP52206398A 1996-11-14 1997-11-14 治療有効成分として脂肪酸類もしくは脂肪族アルコール類またはそれらのモノグリセライド誘導体を含有する粘膜感染症治療用局所製剤 Ceased JP2001504461A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IS4386 1996-11-14
IS4386 1996-11-14
PCT/DK1997/000524 WO1998020872A1 (en) 1996-11-14 1997-11-14 Topical formulations containing as a therapeutic active agent fatty acids or fatty alcohols or monoglyceride derivatives thereof for treating of mucosa infections

Publications (2)

Publication Number Publication Date
JP2001504461A true JP2001504461A (ja) 2001-04-03
JP2001504461A5 JP2001504461A5 (enExample) 2005-07-14

Family

ID=36699955

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52206398A Ceased JP2001504461A (ja) 1996-11-14 1997-11-14 治療有効成分として脂肪酸類もしくは脂肪族アルコール類またはそれらのモノグリセライド誘導体を含有する粘膜感染症治療用局所製剤

Country Status (10)

Country Link
US (1) US6596763B1 (enExample)
EP (1) EP0941087B1 (enExample)
JP (1) JP2001504461A (enExample)
AP (1) AP1209A (enExample)
AT (1) ATE442844T1 (enExample)
AU (1) AU729546B2 (enExample)
CA (1) CA2271843A1 (enExample)
DE (1) DE69739583D1 (enExample)
IS (1) IS5051A (enExample)
WO (1) WO1998020872A1 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008533052A (ja) * 2005-03-10 2008-08-21 スリーエム イノベイティブ プロパティズ カンパニー 抗ウイルス性組成物および使用方法
WO2009081611A1 (ja) * 2007-12-26 2009-07-02 Taiyo Corporation 抗菌剤及びそれを含有する口腔用組成物並びに飲食品
JP2012097038A (ja) * 2010-11-02 2012-05-24 Kao Corp オートインデューサー−２阻害剤
US8455022B2 (en) 2003-10-09 2013-06-04 Medigene Ag Use of a polyphenol for the treatment of a cancerous or precancerous lesion of the skin
US9770406B2 (en) 2001-11-19 2017-09-26 Medigene Ag Medicament for the treatment of viral skin and tumour diseases
JP2018177735A (ja) * 2017-04-20 2018-11-15 マイクロアルジェコーポレーション株式会社 モノアシルグリセロール、抗菌剤、及びモノアシルグリセロールの製造方法
JP2019521134A (ja) * 2016-07-11 2019-07-25 ヘネピン・ライフ・サイエンシーズ・エルエルシーＨｅｎｎｅｐｉｎ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ，Ｌｌｃ 性感染症用組成物
JP2019527240A (ja) * 2016-06-20 2019-09-26 カプレット エーホーエフ． 脂質の抗微生物効果を増大する相乗効果

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19648545B4 (de) † 1996-11-25 2009-05-07 Ceramtec Ag Monolithischer Vielschichtaktor mit Außenelektroden
ES2202872T3 (es) 1997-06-20 2004-04-01 Prometics Bodycare Limited Composicion protectora de la piel.
US6096332A (en) * 1998-06-30 2000-08-01 Mcneil-Ppc, Inc. Adding pharmaceutically active compounds to substrates
RU2186563C2 (ru) * 2000-02-25 2002-08-10 Государственное унитарное предприятие Тихоокеанский научно-исследовательский рыбохозяйственный центр Средство для лечения ожоговой раны
IL137559A (en) * 2000-07-27 2006-12-31 Amnon Sintov A system for administering drugs through the skin
AU2002221412B2 (en) * 2000-12-05 2006-04-13 Alexander Macgregor Hydrostatic delivery system for controlled delivery of agent
DE10156794B4 (de) * 2001-11-19 2006-05-18 Medigene Ag Arzneimittel zur Behandlung von Warzen
US20050032896A1 (en) * 2002-06-21 2005-02-10 Liisa Neumann Use of synthetic retinoic acid in form of 13-cis vitamin A for treatment of autism
US20050095281A1 (en) * 2003-03-14 2005-05-05 Optime Therapeutics, Inc. Liposomal formulations and methods of use
ES2237298B1 (es) 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
GB0317999D0 (en) * 2003-07-31 2003-09-03 Univ Liege Improvements in or relating to drug delivery systems
US20050058673A1 (en) 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
KR101232924B1 (ko) * 2003-09-09 2013-02-13 쓰리엠 이노베이티브 프로퍼티즈 컴파니 농축된 항균 조성물 및 방법
US20050079235A1 (en) * 2003-10-09 2005-04-14 Eggert Stockfleth Use of a polyphenol for the treatment of actinic keratosis
US20070276049A1 (en) * 2003-11-11 2007-11-29 Schlievert Patrick M Regulation of Cell Membrane-Mediated Effects
US8796332B2 (en) 2004-08-03 2014-08-05 Regents Of The University Of Minnesota Compositions and methods for controlling infections
CA2578404A1 (en) * 2004-08-23 2006-03-02 Auckland Uniservices Limited Gastric therapies and compositions therefor
US8535709B2 (en) * 2004-12-13 2013-09-17 Southeastern Medical Technologies, Llc Agents for controlling biological fluids and methods of use thereof
ES2411054T3 (es) * 2004-12-17 2013-07-04 Halldor Thormar Emulsiones antibacterianas concentradas estables de monocaprina en agua
TW200719884A (en) 2005-03-10 2007-06-01 3M Innovative Properties Co Methods of treating ear infections
WO2006099359A2 (en) 2005-03-10 2006-09-21 3M Innovative Properties Company Methods of reducing microbial contamination
CA2598985A1 (en) * 2005-03-10 2006-09-21 3M Innovative Properties Company Antimicrobial pet wipes and methods
MX2007010908A (es) 2005-03-10 2007-12-05 3M Innovative Properties Co Composiciones antimicrobianas que comprenden esteres de acidos hidroxicarboxilicos.
US20080075793A1 (en) * 2006-09-21 2008-03-27 Dunshee Wayne K Antiviral compositions and methods of use
DK2060192T3 (en) * 2007-10-17 2016-02-22 Wild Gmbh & Co Kg Rudolf Composition comprising lemon balm extracts
ES2344673B1 (es) 2008-08-07 2011-05-03 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farmaceutica parael tratamiento de atrofia vaginal en mujeres con riesgo de potologiatumoral.
ES2344675B1 (es) 2008-12-19 2011-04-28 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.
DE102009008094A1 (de) 2009-02-09 2010-08-19 Barnikol-Keuten, Doris, Dr. In situ Haft-Gelbildende Zubereitungen, insbesondere zur topischen Anwendung auf befeuchtete Haut/Schleimhaut
RU2516279C2 (ru) 2009-08-06 2014-05-20 Анитокс Корпорейшн Консервант для воды и корма
JP5864429B2 (ja) 2009-11-09 2016-02-17 スポットライト テクノロジー パートナーズ エルエルシーＳｐｏｔｌｉｇｈｔ Ｔｅｃｈｎｏｌｏｇｙ Ｐａｒｔｎｅｒｓ Ｌｌｃ 架橋ヒドロゲル組成物、ヒドロゲル組成物の形成方法、及びキット
AU2010314994B2 (en) 2009-11-09 2016-10-06 Spotlight Technology Partners Llc Fragmented hydrogels
PH12013500117B1 (en) 2010-08-27 2019-07-17 Anitox Corp Antimicrobial formulation
WO2012035751A1 (ja) * 2010-09-14 2012-03-22 日油株式会社 除菌洗浄剤組成物
US20130261146A1 (en) * 2010-12-09 2013-10-03 The Research Foundation Of State University Of New York Nitric oxide and its biomedical significance
CA2832490C (en) 2011-04-13 2016-06-21 Biosafe Technologies, Inc. Compositions for internal and external insecticides, ovicides, repellents and wound healing
CA2848777A1 (en) 2011-10-20 2013-04-25 Anitox Corporation Antimicrobial formulations with pelargonic acid
JP2015504312A (ja) 2011-11-30 2015-02-12 アニトックス コーポレーション アルデヒド、有機酸及び有機酸エステルの抗微生物混合物
US11246872B2 (en) 2019-06-14 2022-02-15 Propella Therapeutics, Inc. Topical acyclovir formulations and uses thereof
US11572342B2 (en) 2020-09-18 2023-02-07 Niche Biopharmaceuticals LLC Antimicrobial and antiviral sulfur containing glycerol monoester derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4406884A (en) * 1981-06-23 1983-09-27 The Procter & Gamble Company Topical antimicrobial composition
US4520132A (en) * 1982-09-27 1985-05-28 Pennwalt Corporation Use of undecylenic acid to treat herpes labialis
AU566647B2 (en) * 1982-09-30 1987-10-29 Union Carbide Corporation Curable epoxy resin molding composition
US5208257A (en) 1986-04-21 1993-05-04 Kabara Jon J Topical antimicrobial pharmaceutical compositions and methods
US5434182A (en) * 1987-12-31 1995-07-18 Isaacs; Charles E. Antibacterial fatty acid compositions
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
NZ250714A (en) * 1990-10-30 1996-05-28 Mcneil Ppc Inc Liquid composition comprising esters of higher fatty acids for use as a vaginal douche and to prevent toxic shock toxin production
IL104283A (en) * 1992-12-30 1996-12-05 Agis Ind 1983 Ltd Non-emulsion antiviral topical pharmaceutical composition comprising acyclovir an aqueous gel agent and an alkali oleate
IL110380A0 (en) 1994-07-20 1994-10-21 Agis Ind 1983 Ltd Antiviral topical pharmaceutical compositions
DK1001759T3 (da) 1996-09-17 2005-10-10 Avanir Pharmaceuticals Virusinhibering med langkædede alkoholer, alkaner, fedtsyrer og amider

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9770406B2 (en) 2001-11-19 2017-09-26 Medigene Ag Medicament for the treatment of viral skin and tumour diseases
US10434059B2 (en) 2001-11-19 2019-10-08 Fougera Pharmaceuticals Inc. Medicament for the treatment of viral skin and tumour diseases
US8455022B2 (en) 2003-10-09 2013-06-04 Medigene Ag Use of a polyphenol for the treatment of a cancerous or precancerous lesion of the skin
US9060998B2 (en) 2003-10-09 2015-06-23 Medigene Ag Use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin
JP2008533052A (ja) * 2005-03-10 2008-08-21 スリーエム イノベイティブ プロパティズ カンパニー 抗ウイルス性組成物および使用方法
WO2009081611A1 (ja) * 2007-12-26 2009-07-02 Taiyo Corporation 抗菌剤及びそれを含有する口腔用組成物並びに飲食品
JP2009155257A (ja) * 2007-12-26 2009-07-16 Taiyo Corp 抗菌剤及びそれを含有する口腔用組成物並びに飲食品
JP2012097038A (ja) * 2010-11-02 2012-05-24 Kao Corp オートインデューサー−２阻害剤
JP2019527240A (ja) * 2016-06-20 2019-09-26 カプレット エーホーエフ． 脂質の抗微生物効果を増大する相乗効果
JP7505883B2 (ja) 2016-06-20 2024-06-25 カプレット エーホーエフ． 脂質の抗微生物効果を増大する相乗効果
JP2019521134A (ja) * 2016-07-11 2019-07-25 ヘネピン・ライフ・サイエンシーズ・エルエルシーＨｅｎｎｅｐｉｎ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ，Ｌｌｃ 性感染症用組成物
JP2018177735A (ja) * 2017-04-20 2018-11-15 マイクロアルジェコーポレーション株式会社 モノアシルグリセロール、抗菌剤、及びモノアシルグリセロールの製造方法

Also Published As

Publication number Publication date
EP0941087B1 (en) 2009-09-16
AU4941197A (en) 1998-06-03
ATE442844T1 (de) 2009-10-15
DE69739583D1 (de) 2009-10-29
US6596763B1 (en) 2003-07-22
WO1998020872A1 (en) 1998-05-22
IS5051A (is) 1999-05-12
CA2271843A1 (en) 1998-05-22
AU729546B2 (en) 2001-02-01
AP1209A (en) 2003-09-30
EP0941087A1 (en) 1999-09-15

Similar Documents

Publication Publication Date Title
US6596763B1 (en) Topical formulations containing as a therapeutic active agent fatty acids or fatty alcohols or monoglyceride derivatives thereof for treating of mucosa infections
CN1878536B (zh) 抗菌组合物和方法
JP4665075B2 (ja) 粘膜または皮膚を冒す疾病の防止または治療のための、または妊娠の防止のための製剤、および、粘膜腔内に局所用製剤を到達させるためのアプリケーター
Kristmundsdóttir et al. Development and evaluation of microbicidal hydrogels containing monoglyceride as the active ingredient
Zaneveld et al. Efficacy and safety of a new vaginal contraceptive antimicrobial formulation containing high molecular weight poly (sodium 4-styrenesulfonate)
DE69828196T2 (de) Verfahren zur vorbeugung und behandlung bakterieller infektionen unter verwendung von celluloseacetatphthalat- oder hydroxyproppylmethylcelluloseträgerstoffen
KR920001461B1 (ko) 안과 액제의 제조방법
US6239182B1 (en) Method for preventing sexually transmitted diseases
Thormar et al. Hydrogels containing monocaprin have potent microbicidal activities against sexually transmitted viruses and bacteria in vitro.
US20120260922A1 (en) Topical use of hydroxytyrosol and derivatives for the prevention of hiv infection
Neyts et al. Hydrogels containing monocaprin prevent intravaginal and intracutaneous infections with HSV‐2 in mice: Impact on the search for vaginal microbicides
CN107405360B (zh) 新颖碘伏组合物及其使用方法
DE3850535T2 (de) Topisch aktive Doppelstrang-RNS-Zusammensetzungen.
US20130274332A1 (en) Ophthalmic composition for contact lens
US6028115A (en) Method for preventing sexually transmitted diseases
US5194451A (en) Systemic anti-inflammatory treatment
US5166219A (en) Systemic anti-inflammatory treatment
Sánchez-López et al. Nanotechnology-based platforms for vaginal delivery of peptide microbicides
US20050043402A1 (en) Methods and formulations for counteracting infection of mucosa or skin
US5380523A (en) High energy coprecipitate of nonoxynol oligomer, PVP and iodine having contraceptive and potent anti-HIV properties
AU2023202580A1 (en) Compositions for sexually transmitted diseases
EP0468122A1 (fr) Composition thérapeutique à base de polihexanide pour le traitement des manifestations cutanées, oculaires et génitales de l'herpès
RU2498810C1 (ru) Средство с 5-аминосалициловой кислотой кверцетином и экстрактом прополиса, обладающее антиоксидантной активностью
HK1186395A (en) Ophthalmic composition for contact lens

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080819

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20090106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090310